Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Tiragolumab + Chemotherapy in Gastric/GEJ Cancer
NCT04933227Phase 2Terminated
- Sponsor
- Roche
- Start
- Aug 2021
- Primary completion
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of tiragolumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Roche. Started Aug 2021; status: terminated.
02
Drugs
tiragolumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04933227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04933227.